• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

瘢痕疙瘩和增生性瘢痕中的明胶酶活性。

Gelatinase activity in keloids and hypertrophic scars.

作者信息

Neely A N, Clendening C E, Gardner J, Greenhalgh D G, Warden G D

机构信息

Shriners Burns Hospital, Cincinnati, OH 45229, USA.

出版信息

Wound Repair Regen. 1999 May-Jun;7(3):166-71. doi: 10.1046/j.1524-475x.1999.00166.x.

DOI:10.1046/j.1524-475x.1999.00166.x
PMID:10417752
Abstract

Keloids and hypertrophic scars are characterized by excessive deposition of collagen, which may result from insufficient protein degradation. Little is known about the levels of two gelatinases, matrix metalloproteinase-2 (72 kD type IV collagenase) and matrix metalloproteinase-9 (matrix metalloproteinase-9; 92 kD type IV collagenase) in these abnormal scars. The purpose of this study was to determine levels of these proteinases in tissue from hypertrophic scars, keloids, and donor skin. Ten hypertrophic scar samples, 9 keloid samples, and 10 donor skin samples were frozen, pulverized, homogenized, clarified by centrifugation, and analyzed for matrix metalloproteinases by quantitative zymography. Identity of matrix metalloproteinases was determined using a conditioned media reference standard, molecular weight ladders, and Western blotting. Levels of matrix metalloproteinase-9 activity were very low or undetectable in all samples. However, matrix metalloproteinase-2 activity was significantly elevated in keloids and hypertrophic scars vs. donor samples: 2.6 and 3.9-fold increases for latent matrix metalloproteinase-2, 7.8 and 6.9-fold increases for active matrix metalloproteinase-2, respectively. We conclude that little matrix metalloproteinase-9 activity (the gelatinase involved in early tissue repair) is present in keloids and hypertrophic scars, while matrix metalloproteinase-2 activity (the gelatinase involved in prolonged tissue remodeling) is present in donor skin and is significantly increased in hypertrophic scars and keloids.

摘要

瘢痕疙瘩和增生性瘢痕的特征是胶原蛋白过度沉积,这可能是由于蛋白质降解不足所致。关于这两种明胶酶,即基质金属蛋白酶-2(72 kD IV型胶原酶)和基质金属蛋白酶-9(92 kD IV型胶原酶)在这些异常瘢痕中的水平,人们了解甚少。本研究的目的是测定增生性瘢痕、瘢痕疙瘩和供体皮肤组织中这些蛋白酶的水平。将10个增生性瘢痕样本、9个瘢痕疙瘩样本和10个供体皮肤样本冷冻、粉碎、匀浆,通过离心澄清,并用定量酶谱法分析基质金属蛋白酶。使用条件培养基参考标准、分子量梯度和蛋白质印迹法确定基质金属蛋白酶的身份。在所有样本中,基质金属蛋白酶-9的活性水平非常低或无法检测到。然而,与供体样本相比,瘢痕疙瘩和增生性瘢痕中基质金属蛋白酶-2的活性显著升高:潜在基质金属蛋白酶-2分别增加2.6倍和3.9倍,活性基质金属蛋白酶-2分别增加7.8倍和6.9倍。我们得出结论,瘢痕疙瘩和增生性瘢痕中几乎不存在基质金属蛋白酶-9的活性(参与早期组织修复的明胶酶),而基质金属蛋白酶-2的活性(参与长期组织重塑的明胶酶)在供体皮肤中存在,并且在增生性瘢痕和瘢痕疙瘩中显著增加。

相似文献

1
Gelatinase activity in keloids and hypertrophic scars.瘢痕疙瘩和增生性瘢痕中的明胶酶活性。
Wound Repair Regen. 1999 May-Jun;7(3):166-71. doi: 10.1046/j.1524-475x.1999.00166.x.
2
Matrix metalloproteinase-2 and -9 activities in human keloids, hypertrophic and atrophic scars: a pilot study.人瘢痕疙瘩、增生性瘢痕和萎缩性瘢痕中基质金属蛋白酶-2和-9的活性:一项初步研究。
Cell Biochem Funct. 2009 Mar;27(2):81-7. doi: 10.1002/cbf.1537.
3
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with different types of scars and keloids.基质金属蛋白酶和金属蛋白酶组织抑制剂在不同类型瘢痕和瘢痕疙瘩患者中的表达。
J Plast Reconstr Aesthet Surg. 2010 Jun;63(6):1015-21. doi: 10.1016/j.bjps.2009.04.021. Epub 2009 May 22.
4
Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3.基于膜型1基质金属蛋白酶诱导基质金属蛋白酶激活级联反应:明胶酶A、明胶酶B和胶原酶3的相关激活
Biochem J. 1998 Apr 15;331 ( Pt 2)(Pt 2):453-8. doi: 10.1042/bj3310453.
5
Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A.大鼠皮肤伤口愈合过程中基质金属蛋白酶的表达:膜型-1基质金属蛋白酶是前明胶酶A的基质激活剂的证据。
J Cell Biol. 1997 Apr 7;137(1):67-77. doi: 10.1083/jcb.137.1.67.
6
Gelatinolytic and type IV collagenolytic activity in bronchiectasis.
Chest. 1994 Oct;106(4):1129-33. doi: 10.1378/chest.106.4.1129.
7
Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders.内皮功能障碍可能在瘢痕疙瘩和增生性瘢痕的发病机制中起关键作用——瘢痕疙瘩和增生性瘢痕可能是血管性疾病。
Med Hypotheses. 2016 Nov;96:51-60. doi: 10.1016/j.mehy.2016.09.024. Epub 2016 Sep 28.
8
Release and activation of matrix metalloproteinase-9 during in vitro mechanical compression in hypertrophic scars.肥厚性瘢痕体外机械压迫过程中基质金属蛋白酶-9的释放与激活
Arch Dermatol. 2002 Apr;138(4):475-8. doi: 10.1001/archderm.138.4.475.
9
Gelatinase activity during wound healing.伤口愈合过程中的明胶酶活性。
Br J Dermatol. 1994 Nov;131(5):634-40. doi: 10.1111/j.1365-2133.1994.tb04974.x.
10
Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases.基质金属蛋白酶-1、-2和-9以及金属蛋白酶组织抑制剂-2在间质性肺疾病中的定位
Lab Invest. 1998 Jun;78(6):687-98.

引用本文的文献

1
The Pathophysiology and Management of Pathologic Scarring-a Contemporary Review.病理性瘢痕的病理生理学与管理——当代综述
Adv Wound Care (New Rochelle). 2025 Jan;14(1):48-64. doi: 10.1089/wound.2023.0185. Epub 2024 Apr 25.
2
Presentation, Management, and Outcomes of Pathologic Scars Within a Pediatric Otolaryngology Practice.儿科耳鼻喉科实践中病理性瘢痕的表现、处理和结局。
Laryngoscope. 2024 Jul;134(7):3127-3135. doi: 10.1002/lary.31320. Epub 2024 Feb 3.
3
The Emerging Therapeutic Targets for Scar Management: Genetic and Epigenetic Landscapes.
瘢痕管理的新兴治疗靶点:遗传和表观遗传景观。
Skin Pharmacol Physiol. 2022;35(5):247-265. doi: 10.1159/000524990. Epub 2022 Jun 13.
4
Exon skipping of TGFβRI affects signalling and ECM expression in hypertrophic scar-derived fibroblasts.转化生长因子β受体I(TGFβRI)的外显子跳跃影响肥厚性瘢痕来源成纤维细胞中的信号传导和细胞外基质表达。
Scars Burn Heal. 2020 May 28;6:2059513120908857. doi: 10.1177/2059513120908857. eCollection 2020 Jan-Dec.
5
Hypertrophic scars and keloids: Overview of the evidence and practical guide for differentiating between these abnormal scars.增生性瘢痕和瘢痕疙瘩:这些异常瘢痕的鉴别证据概述和实用指南。
Exp Dermatol. 2021 Jan;30(1):146-161. doi: 10.1111/exd.14121. Epub 2020 Jul 6.
6
The evidence for natural therapeutics as potential anti-scarring agents in burn-related scarring.天然疗法作为烧伤相关性瘢痕潜在抗瘢痕形成药物的证据。
Burns Trauma. 2016 May 4;4:15. doi: 10.1186/s41038-016-0040-1. eCollection 2016.
7
Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways.索拉非尼通过拮抗TGF-β/Smad和MAPK/ERK信号通路发挥抗瘢痕疙瘩活性。
J Mol Med (Berl). 2016 Oct;94(10):1181-1194. doi: 10.1007/s00109-016-1430-3. Epub 2016 Jun 24.
8
Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study.二氧化碳点阵激光治疗增生性瘢痕和瘢痕疙瘩:一项临床、组织学及免疫组织化学研究
Lasers Med Sci. 2016 Jan;31(1):9-18. doi: 10.1007/s10103-015-1824-4.
9
Hsp70 Knockdown by siRNA Decreased Collagen Production in Keloid Fibroblasts.通过小干扰RNA敲低热休克蛋白70可降低瘢痕疙瘩成纤维细胞中胶原蛋白的产生。
Yonsei Med J. 2015 Nov;56(6):1619-26. doi: 10.3349/ymj.2015.56.6.1619.
10
Magnesium Ascorbyl Phosphate Regulates the Expression of Inflammatory Biomarkers in Cultured Sebocytes.抗坏血酸磷酸镁调节培养的皮脂腺细胞中炎症生物标志物的表达。
Ann Dermatol. 2015 Aug;27(4):376-82. doi: 10.5021/ad.2015.27.4.376. Epub 2015 Jul 29.